Price Alert

BioXcel Therapeutics Inc. (BTAI)

NASDAQ: BTAI · Real-Time Price · USD

3.79

0.22 (6.16%)

At close: Sep 05, 2025, 3:59 PM

3.88

2.37%

After-hours: Sep 05, 2025, 07:55 PM EDT

6.16% (1D)

Bid	3.79
Market Cap	22.95M
Revenue (ttm)	868K
Net Income (ttm)	-50.95M
EPS (ttm)	-11.9
PE Ratio (ttm)	-0.32
Forward PE	-1.17
Analyst	Buy

Ask	3.99
Volume	2,793,818
Avg. Volume (20D)	9,465,420
Open	3.56
Previous Close	3.57
Day's Range	3.56 - 4.04
52-Week Range	1.17 - 13.36
Beta	0.21

About BTAI

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol BTAI

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for BTAI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

BioXcel Therapeutics Inc. is scheduled to release its earnings on Nov 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+1.55%

BioXcel Therapeutics shares are trading higher aft... Unlock content with Pro Subscription

2 weeks ago

+3.47%

BioXcel Therapeutics shares are trading higher after the company announced it has achieved alignment with the FDA on its sNDA package to expand IGALMI.

News

1 week ago · benzinga.com

BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment

BioXcel Therapeutics Inc. BTAI announced that its SERENITY At-Home Phase 3 trial of BXCL501—its sublingual dexmedetomidine film for acute agitation in bipolar disorder or schizophrenia—met its primary...

3 weeks ago · zacks.com

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Lags Revenue Estimates

BioXcel Therapeutics, Inc. (BTAI) came out with a quarterly loss of $2.45 per share versus the Zacks Consensus Estimate of a loss of $2.3. This compares to a loss of $3.36 per share a year ago.

2 months ago · https://www.defenseworld.net

Squarepoint Ops LLC Acquires 48,336 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)

Squarepoint Ops LLC grew its stake in shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI – Free Report) by 203.9% during the fourth quarter, according to the company in its most recent 13F filing...